Bon Natural Life (BON) AI Stock Analysis

• Market Cap: $11.62M
• Dividend Yield: N/A
• Average Volume (3M): 2.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.84
• Revenue Growth: -15.44%
• EPS Growth: -94.04%
• Country: US
• Employees: 97
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Packaged Foods
• EPS (TTM): N/A
• Shares Outstanding: 6,086,971
• 10 Day Avg. Volume: 115,576
• 30 Day Avg. Volume: 2,242,045
• PEG Ratio: <0.01
• Price to Book (P/B): 0.09
• Price to Sales (P/S): 0.29
• P/FCF Ratio: -1.27
• Enterprise Value/Market Cap: 1.27
• Enterprise Value/Revenue: 0.79
• Enterprise Value/Gross Profit: 3.81
• Enterprise Value/Ebitda: 673.25
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $1.50 ▼(-11.76% Downside)
• Action: Downgraded Date: 01/26/26
• Date: Action: Downgraded 01/26/26

The score is primarily constrained by weak financial performance—especially persistent negative free cash flow and deteriorating profitability. Technical indicators are mixed/neutral with mild bearish momentum, and valuation is challenging due to losses (negative P/E) with no dividend support.

Positive Factors

Balance-sheet buffer

A low debt-to-equity ratio and materially higher equity provide a durable financial cushion. This buffer supports funding operations, absorbing losses, and securing financing if needed, increasing resilience while management addresses profitability and cash-generation shortfalls.

AI-driven biomanufacturing partnership

The joint lab and multi-year cooperation institutionalize R&D and scale-up capabilities. AI-enhanced biomanufacturing can lower unit costs, improve supply reliability and product differentiation, strengthening long-term competitive position in natural active ingredients.

Proven prior profitability

A history of multi-year profitability indicates the underlying business model and market demand are viable. That track record suggests management can restore margins and returns if they address cost structure and revenue drivers, making recovery feasible over months.

Negative Factors

Persistent negative cash flow

Sustained negative free cash flow and minimal operating cash generation undermine the company’s ability to self-fund growth or weather shocks. Over months this forces reliance on external financing, raising dilution or leverage risk and constraining strategic investments.

Revenue and margin erosion

Declining sales and a sharp margin squeeze indicate weakening pricing power or higher input costs. This structural deterioration reduces the firm's ability to regain consistent profitability and raises the bar for successful turnaround initiatives over the medium term.

Leadership and governance risk

A sudden technical leader departure and replacement by a close relative elevates governance and succession risk. Even with credentials, family ties can impair independent oversight, deter partners or investors, and create long-term execution and credibility challenges.

Bon Natural Life Business Overview & Revenue Model

Company Description

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.

How the Company Makes Money

Bon Natural Life (BON) primarily makes money by selling its natural health and wellness products (e.g., dietary supplements and related consumer health goods) to customers through its distribution and sales channels. Revenue is generated from product sales, with earnings influenced by product mix, sales volume, pricing, and the reach/effectiveness of its distribution network. Specific details on the breakdown of revenue by product category, the exact sales channels used (e.g., direct-to-consumer vs. wholesale), major customer concentrations, significant partnerships, and other material revenue drivers are null.

Bon Natural Life Financial Statement Overview

Summary

Overall fundamentals are weak: the income statement shows falling revenue, margin compression, and a swing to a net loss in 2025, while cash flow is a major red flag with persistently negative free cash flow and very thin/negative operating cash flow. The balance sheet is a relative support with low debt-to-equity and higher equity, but rising debt and negative ROE increase risk if profitability does not recover.

Income Statement

Profitability has deteriorated sharply. Revenue fell to $18.7M in 2025 (down ~14% year over year) after earlier years of stronger sales, and margins compressed meaningfully (gross margin ~21% vs ~30% in 2023–2024). The company swung from a modest profit in 2024 to a net loss of about $2.0M in 2025, with operating results also turning negative—signaling weakening pricing/power and/or higher cost pressure. Strength: the business demonstrated solid profitability in 2020–2023, showing the model can work in better conditions.

Balance Sheet

Leverage appears manageable, with debt-to-equity around 0.21 in 2025 (still relatively low). Equity has grown over time (about $57.6M in 2025 vs $10.5M in 2020), providing a balance-sheet buffer. Weakness: returns on equity flipped negative in 2025 due to the loss, and total debt has risen notably versus prior years (about $12.3M in 2025 vs $7.3M in 2024), which increases risk if profitability does not recover.

Cash Flow

Cash generation is a major concern. Free cash flow is consistently negative across the period and worsened to about -$4.2M in 2025, while cash generated from core operations is extremely thin in 2025 (~$0.14M) and was negative in multiple prior years (notably 2022–2024). The mix of losses (2025) and ongoing cash burn suggests reliance on external funding or balance-sheet liquidity to sustain investment and operations. Strength: the company did generate positive operating cash flow in 2020 and 2021, but this has not been sustained.

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	18.67M	23.84M	29.52M	29.91M	25.49M
Gross Profit	3.88M	7.11M	8.84M	9.42M	7.11M
EBITDA	-57.83K	2.30M	6.98M	8.33M	6.13M
Net Income	-1.99M	398.17K	4.60M	6.24M	4.59M
Balance Sheet
Total Assets	85.19M	61.77M	46.56M	37.26M	36.41M
Cash, Cash Equivalents and Short-Term Investments	6.27M	80.47K	111.30K	840.86K	3.61M
Total Debt	12.32M	7.30M	4.21M	5.41M	3.21M
Total Liabilities	27.19M	17.42M	10.57M	7.16M	9.88M
Stockholders Equity	57.55M	43.91M	35.48M	29.56M	26.01M
Cash Flow
Free Cash Flow	-4.23M	-7.73M	-713.82K	-4.92M	-700.78K
Operating Cash Flow	141.12K	-7.72M	-651.91K	-187.12K	4.05M
Investing Cash Flow	-10.00M	-15.73K	-1.19M	-3.06M	-7.44M
Financing Cash Flow	15.45M	8.76M	1.16M	2.26M	5.35M

Bon Natural Life Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BON, the sentiment is Negative. The current price of 1.7 is above the 20-day moving average (MA) of 1.53, above the 50-day MA of 1.61, and above the 200-day MA of 1.66, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 34.19 is Neutral, neither overbought nor oversold. The STOCH value of 52.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BON.

Bon Natural Life Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
LSF	52 Neutral	$25.58M	-15.26	-14.36%	―	17.73%	-34.71%
BON	46 Neutral	$11.62M	-2.69	-3.59%	―	-15.44%	-94.04%
HCWC	46 Neutral	$5.24M	-1.06	-74.59%	―	―	―
NAII	44 Neutral	$15.81M	-2.11	-17.43%	―	18.19%	-35.22%
FAMI	42 Neutral	$17.41M	-0.07	-36.55%	―	-49.19%	-394.71%

Bon Natural Life Corporate Events

Bon Natural Life Names New CTO After Sudden March Resignation

On March 12, 2026, Bon Natural Life’s Chief Technology Officer and Chief Scientist, Jianli Liu, resigned from all his positions with immediate effect, with the company stating there were no known disagreements related to its operations, policies or practices. The leadership change removes a long-standing technical head but appears orderly, limiting potential disruption to ongoing projects.

Effective March 16, 2026, the company appointed director Jing Liu, who is also the wife of controller and CEO-level figure Hu Yongwei, as its new Chief Technology Officer under a three-year employment contract. Her extensive academic background in chemical engineering, supramolecular chemistry and new energy technologies suggests a stronger emphasis on R&D capabilities, while her family ties to management underscore the company’s reliance on a closely connected leadership structure.

The most recent analyst rating on (BON) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bon Natural Life stock, see the BON Stock Forecast page.

Bon Natural Life Deepens AI-Driven Biomanufacturing Push With Chang’an Pilot Joint Lab

Bon Natural Life Limited, a Nasdaq-listed supplier of natural active ingredients for health and personal care products, operates globally with a portfolio spanning plant-based extracts, functional food ingredients and personal care actives. The company relies on advanced extraction and biosynthesis technologies, including an AI-driven bio-manufacturing platform, to support large-scale, high-quality production for customers in major markets worldwide.

On January 22, 2026, Bon’s subsidiary Xi’an App-Chem Bio-Tech Co., Ltd. signed a three-year framework cooperation agreement with Shaanxi Chang’an Pilot Life Science Industry Innovation Center to build an integrated innovation chain from basic research to industrial application. Under this collaboration, formally highlighted on February 17, 2026, the parties inaugurated the BON & Pilot Joint Laboratory on December 18, 2025 to develop AI-enhanced biomanufactured natural ingredients, and plan an engineering center plus broader R&D, market and capital partnerships that could bolster Bon’s efficiency, supply reliability and competitive position in bio-manufactured ingredients.

The most recent analyst rating on (BON) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bon Natural Life stock, see the BON Stock Forecast page.